BLAINJECTIONINJECTABLE
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
JOBEVNE (bevacizumab-nwgd) by Biocon is vascular endothelial growth factor-directed antibody interactions [moa]. First approved in 2025.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JOBEVNE is a bevacizumab biosimilar (BEVACIZUMAB-NWGD) developed by Biocon, approved April 2025. It is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancers. The drug is indicated for multiple oncology indications where VEGF inhibition is therapeutic, primarily solid tumors.
Launch
Early-stage biosimilar launch with moderate competitive pressure (30%) creates opportunity for launch team building in market access, medical science, and field commercial roles.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
JOBEVNE is a launch-stage biosimilar with moderate competitive intensity, offering entry and growth opportunities for professionals in field sales, medical affairs, and market access roles. Career trajectory is tied to Biocon's ability to gain formulary position, payer contracts, and clinical adoption in a crowded biosimilar marketplace.
Brand Manager
Worked on JOBEVNE at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.